PharmaVOICE 2020 Year in Preview features precision medicine insight of CEO of Diaceutics Peter Keeling

The thought leadership of Peter Keeling, the CEO of Diaceutics, is featured in the PharmaVOICE’s 2020 Year in Preview issue (Nov/Dec 2019). Keeling is one of 130+ precision medicine experts selected to comment on 20 provocative questions regarding changes needed to “address inefficiency and productivity to achieve aspirational goals for healthcare in the future.” 

Keeling’s insight into the future possibilities for precision medicine is featured on page 32 in the opening article, entitled “The Year Ahead.” Keeling responded to the question “What if the promise of personalized medicine was realized?” with the following:

The following quote from Keeling is featured on page 85 in the article entitled “Patient Care: Treatment to Cure,” under “Early detection key to improving health” sidebar:

For more insights on and predictions for Precision Medicine in the year ahead, read the Diaceutics PM Readiness Report. 

Webinars & Podcasts

Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases....
Liquid Biopsy in NSCLC
View all

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports


FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with >5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved...
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of...
View all publications